Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Lilly

Revenues down 10% impacted by Zyprexa patent expiry

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly
 
2Q Revenues: $5.6 billion (-10%)
 
2Q Earnings: $923.6 million (-23%)
 
YTD Revenues: $11.2 billion (-7%)
 
YTD Earnings: $1.9 billion (-14%)
 
Comments: U.S. sales were down 10% to $3.0 billion and revenue outside the U.S. was down 11% to $2.6 billion due to the loss of patent exclusivity for Zyprexa (-73%). Cymbalta revenue increased 22% to $1.2 billion. Alimta sales were $659.5million (+8%). Humalog sales were $613.4 million (+4%). Cialis sales were down 2% to $469.5 million. Forteo sales were up 20% to $276.4 million. Effient sales were up 55% to $111 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters